Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.68 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.68 |
| ▸ | PTGER4 | P35408 | 11/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 11/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 11/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9199596 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL9199602 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL3363176 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL9204592 | 0.80 | LTB4R (0.69) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL9204585 | 0.80 | LTB4R (0.69) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL4031129 | 0.75 | KDM4E (0.65) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL4031132 | 0.75 | KDM4E (0.65) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL344775 | 0.73 | PTGER4 (0.70) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL344776 | 0.73 | PTGER4 (0.70) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL4029676 | 0.73 | KDM4E (0.65) | LTB4RLTB4R2PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | LTB4R 1737/4885LTB4R2 1873/4885PTGER4 762/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | LTB4R 2160/4885LTB4R2 2448/4885PTGER4 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.